SG11201906939XA - Interaction between c-peptides and elastin receptor, a model for understanding vascular disease - Google Patents

Interaction between c-peptides and elastin receptor, a model for understanding vascular disease

Info

Publication number
SG11201906939XA
SG11201906939XA SG11201906939XA SG11201906939XA SG11201906939XA SG 11201906939X A SG11201906939X A SG 11201906939XA SG 11201906939X A SG11201906939X A SG 11201906939XA SG 11201906939X A SG11201906939X A SG 11201906939XA SG 11201906939X A SG11201906939X A SG 11201906939XA
Authority
SG
Singapore
Prior art keywords
elastin
international
peptide
lock
rule
Prior art date
Application number
SG11201906939XA
Other languages
English (en)
Inventor
Gert Wensvoort
Original Assignee
Resiliun B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resiliun B V filed Critical Resiliun B V
Publication of SG11201906939XA publication Critical patent/SG11201906939XA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201906939XA 2017-02-06 2018-02-05 Interaction between c-peptides and elastin receptor, a model for understanding vascular disease SG11201906939XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17154889 2017-02-06
PCT/EP2018/052824 WO2018141970A1 (en) 2017-02-06 2018-02-05 Interaction between c-peptides and elastin receptor, a model for understanding vascular disease

Publications (1)

Publication Number Publication Date
SG11201906939XA true SG11201906939XA (en) 2019-08-27

Family

ID=57995050

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201906939XA SG11201906939XA (en) 2017-02-06 2018-02-05 Interaction between c-peptides and elastin receptor, a model for understanding vascular disease
SG11201906943VA SG11201906943VA (en) 2017-02-06 2018-02-05 Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201906943VA SG11201906943VA (en) 2017-02-06 2018-02-05 Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use

Country Status (8)

Country Link
US (4) US20200087374A1 (https=)
EP (3) EP3570875B1 (https=)
JP (2) JP7438757B2 (https=)
AU (2) AU2018215245B2 (https=)
CA (2) CA3051293A1 (https=)
ES (1) ES2927977T3 (https=)
SG (2) SG11201906939XA (https=)
WO (2) WO2018141970A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6982395B2 (ja) * 2017-03-16 2021-12-17 三洋化成工業株式会社 インターロイキン１０の産生量増加剤
WO2019104391A1 (en) * 2017-12-01 2019-06-06 St Vincent's Institute Of Medical Research Type 1 diabetes treatment
EP4021481A1 (en) * 2019-08-30 2022-07-06 Biotempt B.V. Q-er peptide
JP6895148B1 (ja) * 2020-03-31 2021-06-30 クラシエホールディングス株式会社 冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定する判定用マーカー、冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定する判定方法、及び冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定するための判定用キット
CN111704653B (zh) * 2020-06-08 2023-10-03 深圳市图微安创科技开发有限公司 靶向于纤连蛋白衍生肽的抑制剂多肽化合物及其用途
CN116847869A (zh) * 2020-10-08 2023-10-03 美商玛丽莫里斯博士联合有限责任公司 用于治疗和预防1型糖尿病的方法和组合物
CN112345770A (zh) * 2020-11-06 2021-02-09 苏州大学附属第一医院 弹性蛋白降解肽作为腹膜透析患者血管钙化标志物的应用
KR102718109B1 (ko) * 2021-10-01 2024-10-17 (주)케어젠 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도
MX2024004304A (es) * 2021-10-05 2024-04-26 Biotempt Bv Control angiogenico, preferiblemente combinado con control glucemico.
JP2025525516A (ja) 2022-07-12 2025-08-05 リシリアン ベー．フェー． 高インスリン血症と関連する低血糖症を伴う状態の処置

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
US6734289B2 (en) * 2001-03-29 2004-05-11 The University Of Chicago Gastrokines and derived peptides including inhibitors
AU2003228382A1 (en) * 2002-03-27 2003-10-13 University Of Utah Research Foundation Elastin prevents occlusion of body vessels by vascular smooth muscle cells
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
GB0323979D0 (en) * 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
GB0412174D0 (en) * 2004-06-01 2004-06-30 Creative Peptides Sweden Ab Degradation-resistant analogues of pro-insulin c-peptide
WO2008118387A2 (en) * 2007-03-23 2008-10-02 Wayne State University Erythrocyte atp-release modulators
EP2480888B1 (en) * 2009-09-25 2016-11-30 XOMA Technology Ltd. Screening methods
WO2013113663A1 (en) * 2012-02-01 2013-08-08 F. Hoffmann-La Roche Ag Method for the detection of a binding partner of a multispecific binder
EP2626704B1 (en) * 2012-02-08 2015-11-18 Mehmet Ali Soylemez Diagnosis of pancreatic diabetes in patients with normal blood leucocyte counts using procalcitonin
RU2672561C2 (ru) * 2012-04-12 2018-11-16 Б.Р.А.Х.М.С Гмбх Прогнозирование нежелательных явлений у пациентов с предполагаемым диагнозом хронической сердечной недостаточности
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
ES2879023T3 (es) * 2013-01-08 2021-11-19 Sphingotec Gmbh Niveles en ayunas de la hormona de crecimiento como marcador predictivo de riesgo cardiovascular
WO2014145836A1 (en) * 2013-03-15 2014-09-18 Health Diagnostic Laboratory, Inc. Method of generating an index score for mbl deficiency to predict cardiodiabetes risk
CN104371003B (zh) * 2013-08-15 2025-09-02 上海市第一人民医院 预防和治疗炎症的小分子多肽及其应用
SG11201607487UA (en) * 2014-03-21 2016-10-28 Sanofi Aventis Deutschland New markers for the assessment of the risk for development of a cardiovascular disorder

Also Published As

Publication number Publication date
AU2018215245B2 (en) 2024-07-11
US20240027431A1 (en) 2024-01-25
JP7438757B2 (ja) 2024-02-27
ES2927977T3 (es) 2022-11-14
EP3570875A1 (en) 2019-11-27
CA3051293A1 (en) 2018-08-09
EP3577462A1 (en) 2019-12-11
US20220009988A1 (en) 2022-01-13
AU2018216033B2 (en) 2021-10-07
EP3577462B1 (en) 2024-04-17
AU2018216033A1 (en) 2019-08-15
WO2018141970A1 (en) 2018-08-09
CA3049738A1 (en) 2018-08-09
EP3570875B1 (en) 2022-07-06
JP2024056838A (ja) 2024-04-23
EP3577462C0 (en) 2024-04-17
WO2018141969A1 (en) 2018-08-09
EP4421088A2 (en) 2024-08-28
AU2018215245A1 (en) 2019-07-25
SG11201906943VA (en) 2019-08-27
US20200087374A1 (en) 2020-03-19
US20250123275A1 (en) 2025-04-17
JP2020507623A (ja) 2020-03-12
EP4421088A3 (en) 2024-12-04

Similar Documents

Publication Publication Date Title
SG11201906939XA (en) Interaction between c-peptides and elastin receptor, a model for understanding vascular disease
SG11201909646TA (en) Trem2 antigen binding proteins and uses thereof
SG11201908650PA (en) Optimized antibody compositions for treatment of ocular disorders
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201903693QA (en) Polypeptide variants and uses thereof
SG11201811737SA (en) Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201810687SA (en) Serum albumin-binding fibronectin type iii domains
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201908540PA (en) Stable antibody formulation
SG11201907209QA (en) Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
SG11201807912SA (en) Vaccine against rsv
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201908784TA (en) Improved antigen binding receptor formats
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201809229VA (en) Pharmaceutical composition
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201810853UA (en) Anti-tnfrsf25 antibodies